Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113294877> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W3113294877 abstract "Abstract BACKGROUND Patients with relapsed CNS malignancies or DIPG face terrible prognoses. We hypothesized that T cells specific for 3 tumor-associated antigens (TAA), WT1, PRAME and survivin, would be safe and elicit anti-tumor immunity. METHODS Patients (n=15) received autologous tumor antigen-associated T cells (TAAT) (up to 4x107/m2) for newly diagnosed DIPG (Group A) or recurrent CNS malignancies (Group B) on a Phase I dose-escalation study (NCT03652545) and were monitored for safety and response. RESULTS/DISCUSSION 15/15 patients who received TAAT completed the 45-day safety monitoring phase with no dose-limiting toxicities. Adverse events were minimal despite multiple pretreatments in Group B. Infused cells were predominantly CD3+ T cells (median 96%; range: 87–99%), with CD4+ and CD8+ comprising 16% (range: 5–87%) and 40% (range: 4–67%) respectively. Specificity for 1–3 TAAs was demonstrated in 13/15 TAAT by a-IFN-γ ELISPOT. Plasma cytokine and proteomic analyses are ongoing but have demonstrated dynamic post-infusion immune cytokine and protein responses. Increases in the inflammatory and immune-stimulatory cytokines IL-1b, IL-6, IL-2 and IL-7 were observed post-infusion in most patients evaluated. Infusion-related increases in regulatory cytokines IL-10 and IL-13 were also observed in 4/7 patients. These results are consistent with an infusion-mediated immune response in vivo. Of 9 patients who have been tested thus far, 29/92 plasma proteins showed significant differences between dose levels 1 and 2, including increased IL-7 (p < 0.0004) and CD40L (p < 0.046) and reduced IL-4 (p < 0.0004). T cell receptor sequencing data on in vivo TAAT persistence is pending. In summary, TAAT have thus far been safe and elicit immune responses in vivo. Clinical and immunologic response assessments are ongoing." @default.
- W3113294877 created "2020-12-21" @default.
- W3113294877 creator A5006134549 @default.
- W3113294877 creator A5009318195 @default.
- W3113294877 creator A5010156605 @default.
- W3113294877 creator A5025567999 @default.
- W3113294877 creator A5039750788 @default.
- W3113294877 creator A5042431577 @default.
- W3113294877 creator A5044312349 @default.
- W3113294877 creator A5044759108 @default.
- W3113294877 creator A5045858447 @default.
- W3113294877 creator A5055376125 @default.
- W3113294877 creator A5057892885 @default.
- W3113294877 creator A5066139971 @default.
- W3113294877 creator A5066848010 @default.
- W3113294877 creator A5066937973 @default.
- W3113294877 creator A5077132028 @default.
- W3113294877 creator A5080987226 @default.
- W3113294877 creator A5082455986 @default.
- W3113294877 creator A5088213305 @default.
- W3113294877 date "2020-11-01" @default.
- W3113294877 modified "2023-09-25" @default.
- W3113294877 title "CTIM-33. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS" @default.
- W3113294877 doi "https://doi.org/10.1093/neuonc/noaa215.167" @default.
- W3113294877 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8168094" @default.
- W3113294877 hasPublicationYear "2020" @default.
- W3113294877 type Work @default.
- W3113294877 sameAs 3113294877 @default.
- W3113294877 citedByCount "0" @default.
- W3113294877 crossrefType "journal-article" @default.
- W3113294877 hasAuthorship W3113294877A5006134549 @default.
- W3113294877 hasAuthorship W3113294877A5009318195 @default.
- W3113294877 hasAuthorship W3113294877A5010156605 @default.
- W3113294877 hasAuthorship W3113294877A5025567999 @default.
- W3113294877 hasAuthorship W3113294877A5039750788 @default.
- W3113294877 hasAuthorship W3113294877A5042431577 @default.
- W3113294877 hasAuthorship W3113294877A5044312349 @default.
- W3113294877 hasAuthorship W3113294877A5044759108 @default.
- W3113294877 hasAuthorship W3113294877A5045858447 @default.
- W3113294877 hasAuthorship W3113294877A5055376125 @default.
- W3113294877 hasAuthorship W3113294877A5057892885 @default.
- W3113294877 hasAuthorship W3113294877A5066139971 @default.
- W3113294877 hasAuthorship W3113294877A5066848010 @default.
- W3113294877 hasAuthorship W3113294877A5066937973 @default.
- W3113294877 hasAuthorship W3113294877A5077132028 @default.
- W3113294877 hasAuthorship W3113294877A5080987226 @default.
- W3113294877 hasAuthorship W3113294877A5082455986 @default.
- W3113294877 hasAuthorship W3113294877A5088213305 @default.
- W3113294877 hasBestOaLocation W31132948771 @default.
- W3113294877 hasConcept C121608353 @default.
- W3113294877 hasConcept C126322002 @default.
- W3113294877 hasConcept C147483822 @default.
- W3113294877 hasConcept C167672396 @default.
- W3113294877 hasConcept C197934379 @default.
- W3113294877 hasConcept C203014093 @default.
- W3113294877 hasConcept C2775975398 @default.
- W3113294877 hasConcept C2777701055 @default.
- W3113294877 hasConcept C2778690821 @default.
- W3113294877 hasConcept C2779053233 @default.
- W3113294877 hasConcept C2780850621 @default.
- W3113294877 hasConcept C3875195 @default.
- W3113294877 hasConcept C502942594 @default.
- W3113294877 hasConcept C71924100 @default.
- W3113294877 hasConcept C8891405 @default.
- W3113294877 hasConceptScore W3113294877C121608353 @default.
- W3113294877 hasConceptScore W3113294877C126322002 @default.
- W3113294877 hasConceptScore W3113294877C147483822 @default.
- W3113294877 hasConceptScore W3113294877C167672396 @default.
- W3113294877 hasConceptScore W3113294877C197934379 @default.
- W3113294877 hasConceptScore W3113294877C203014093 @default.
- W3113294877 hasConceptScore W3113294877C2775975398 @default.
- W3113294877 hasConceptScore W3113294877C2777701055 @default.
- W3113294877 hasConceptScore W3113294877C2778690821 @default.
- W3113294877 hasConceptScore W3113294877C2779053233 @default.
- W3113294877 hasConceptScore W3113294877C2780850621 @default.
- W3113294877 hasConceptScore W3113294877C3875195 @default.
- W3113294877 hasConceptScore W3113294877C502942594 @default.
- W3113294877 hasConceptScore W3113294877C71924100 @default.
- W3113294877 hasConceptScore W3113294877C8891405 @default.
- W3113294877 hasLocation W31132948771 @default.
- W3113294877 hasLocation W31132948772 @default.
- W3113294877 hasLocation W31132948773 @default.
- W3113294877 hasOpenAccess W3113294877 @default.
- W3113294877 hasPrimaryLocation W31132948771 @default.
- W3113294877 hasRelatedWork W12580093 @default.
- W3113294877 hasRelatedWork W14687542 @default.
- W3113294877 hasRelatedWork W158596 @default.
- W3113294877 hasRelatedWork W19160979 @default.
- W3113294877 hasRelatedWork W19983576 @default.
- W3113294877 hasRelatedWork W6021060 @default.
- W3113294877 hasRelatedWork W7425409 @default.
- W3113294877 hasRelatedWork W7677563 @default.
- W3113294877 hasRelatedWork W15255855 @default.
- W3113294877 hasRelatedWork W18343434 @default.
- W3113294877 isParatext "false" @default.
- W3113294877 isRetracted "false" @default.
- W3113294877 magId "3113294877" @default.
- W3113294877 workType "article" @default.